RxDoctor Payments Data

Yongxin Chen, MD

Allergy & Immunology · Katy, TXNPI 1801899737

Payments from drug & device makers

$10,318in general payments, 2019–2025

Across 567 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$765
  • Novartis$589
  • Optinose US, Inc.$415
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$10,284100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,318 in reported general payments places this provider in the 60th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$126,621
Medicare patients
182
Services billed
9,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$59,932
Breo ElliptaFluticasone/Vilanterol44$23,414
Advair HfaFluticasone Propion/Salmeterol19$10,663
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,149
Azelastine Hcl128$5,961
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$5,860
BreynaBudesonide/Formoterol Fumarate18$5,466
SymbicortBudesonide/Formoterol Fumarate16$4,825
Qvar RedihalerBeclomethasone Dipropionate11$3,785
Wixela InhubFluticasone Propion/Salmeterol20$3,767
Albuterol Sulfate HfaAlbuterol Sulfate109$2,892
Epinephrine22$2,459
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$1,963
Montelukast Sodium195$1,956
Ipratropium Bromide21$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,668$83,345112 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,436$14,97430 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$269$3,78511 claims
Hikma Pharmaceuticals USAEpinephrine$43$2,45922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →